{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:50:44Z","timestamp":1792608644664,"version":"4.5.0"},"reference-count":42,"publisher":"BMJ","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001547","name":"China Medical Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj-2022-069963","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T12:25:12Z","timestamp":1686831912000},"page":"e069963","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy"],"prefix":"10.1136","volume":"381","author":[{"given":"Yingyao","family":"Chen","sequence":"first","affiliation":[{"name":"School of Public Health, Fudan University, Shanghai 200032, China"},{"name":"National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengjin","family":"Dong","sequence":"additional","affiliation":[{"name":"Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Public Health, Fudan University, Shanghai 200032, China"},{"name":"National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Public Health, Fudan University, Shanghai 200032, China"},{"name":"National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ming","sequence":"additional","affiliation":[{"name":"School of Public Health, Fudan University, Shanghai 200032, China"},{"name":"National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"2025110101542143000_381.jun14_11.e069963.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"2025110101542143000_381.jun14_11.e069963.2","unstructured":"People\u2019s Republic of China. Opinions on the reform of the review and approval system to encourage innovation in drugs and medical devices. 2017. http:\/\/www.gov.cn\/zhengce\/2017-10\/08\/content_5230105.htm"},{"key":"2025110101542143000_381.jun14_11.e069963.3","unstructured":"Jie He JL Ma J Qin S Jiang Z . Chinese Society of Clinical Oncology common malignant neoplasm treatment guidelines consolidated book 2021. People's Medical Publishing House, 2021."},{"key":"2025110101542143000_381.jun14_11.e069963.4","unstructured":"Ministry of Finance, General Administration of Customs, State Taxation Administration, et al. Notice of value added tax policy on anti-cancer drugs. 2018. http:\/\/www.gov.cn\/zhengce\/zhengceku\/2018-12\/31\/content_5439687.htm"},{"key":"2025110101542143000_381.jun14_11.e069963.5","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. 2021 https:\/\/www.nccn.org\/guidelines\/category_1"},{"key":"2025110101542143000_381.jun14_11.e069963.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"2025110101542143000_381.jun14_11.e069963.7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2025110101542143000_381.jun14_11.e069963.8","doi-asserted-by":"publisher","DOI":"10.1038\/35077246"},{"key":"2025110101542143000_381.jun14_11.e069963.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2015.07.008"},{"key":"2025110101542143000_381.jun14_11.e069963.10","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2017.03.11"},{"key":"2025110101542143000_381.jun14_11.e069963.11","unstructured":"World Health Organization. Health intervention and technology assessment in support of universal health coverage. 2014. https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA67\/A67_R23-en.pdf?ua=1"},{"key":"2025110101542143000_381.jun14_11.e069963.12","unstructured":"National Medical Products Administration. China listed drug inventory collection database. https:\/\/www.cde.org.cn\/hymlj\/listpage\/9cd8db3b7530c6fa0c86485e563f93c7"},{"key":"2025110101542143000_381.jun14_11.e069963.13","unstructured":"Observer TE. Dialogue with Xiong Xianjun from National Healthcare Security Administration: the pursuit of national drug price negotiation is not the lowest price, but a reasonable price. 2021. http:\/\/www.eeo.com.cn\/2021\/0122\/460379.shtml"},{"key":"2025110101542143000_381.jun14_11.e069963.14","unstructured":"National Healthcare Security Administration. Announcement on the work plan for the adjustment of the national reimbursement drug list in 2021 and the guidelines for reporting adjustments to the national reimbursement drug list in 2021. http:\/\/www.nhsa.gov.cn\/art\/2021\/6\/30\/art_62_5386.html"},{"key":"2025110101542143000_381.jun14_11.e069963.15","unstructured":"National Healthcare Security Administration. Notice on the inclusion of the 2019 negotiated drugs into the category B scope of the national reimbursement drug list for basic medical insurance, work injury insurance and maternity insurance. 2019. http:\/\/www.gov.cn\/xinwen\/2019-11\/28\/content_5456662.htm"},{"key":"2025110101542143000_381.jun14_11.e069963.16","unstructured":"Three PD-1 drugs were included in the updated national reimbursement drug list 2020, with an average price reduction of nearly 80%. China Central Television, 28 Dec 2020. http:\/\/tv.cctv.com\/2020\/12\/28\/VIDEDD61lsrsuGl9ACPFAtYS201228.shtml"},{"key":"2025110101542143000_381.jun14_11.e069963.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"},{"key":"2025110101542143000_381.jun14_11.e069963.18","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1570221"},{"key":"2025110101542143000_381.jun14_11.e069963.19","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1899813"},{"key":"2025110101542143000_381.jun14_11.e069963.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2116863"},{"key":"2025110101542143000_381.jun14_11.e069963.21","doi-asserted-by":"publisher","DOI":"10.1057\/palcomms.2016.92"},{"key":"2025110101542143000_381.jun14_11.e069963.22","doi-asserted-by":"publisher","DOI":"10.7551\/mitpress\/3292.001.0001"},{"key":"2025110101542143000_381.jun14_11.e069963.23","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462310000395"},{"key":"2025110101542143000_381.jun14_11.e069963.24","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-appraisal-of-the-evidence-and-structured-decision-making#decision-making"},{"key":"2025110101542143000_381.jun14_11.e069963.25","unstructured":"Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the pharmaceutical benefits advisory committee (Version 5.0). 2016. https:\/\/pbac.pbs.gov.au\/information\/about-the-guidelines.html"},{"key":"2025110101542143000_381.jun14_11.e069963.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.11.002"},{"key":"2025110101542143000_381.jun14_11.e069963.27","unstructured":"National Healthcare Security Administration. Work plan for the adjustment of the national reimbursement drug list in 2021. 2021. http:\/\/www.nhsa.gov.cn\/art\/2021\/6\/30\/art_109_6616.html"},{"key":"2025110101542143000_381.jun14_11.e069963.28","unstructured":"National Institute for Health and Care Excellence. Guide to the processes of technology appraisal. 2018. https:\/\/www.nice.org.uk\/process\/pmg19\/chapter\/the-appraisal-process#table-3-expected-timelines-for-the-appraisal-process-starting-the-process-preparing-the-erg-report"},{"key":"2025110101542143000_381.jun14_11.e069963.29","unstructured":"Pharmaceutical Benefits Advisory Committee. PBAC cycle timeframe for 2022-2023. 2022. https:\/\/www.pbs.gov.au\/pbs\/industry\/useful-resources\/pbs-calendar"},{"key":"2025110101542143000_381.jun14_11.e069963.30","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16020288"},{"key":"2025110101542143000_381.jun14_11.e069963.31","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14337"},{"key":"2025110101542143000_381.jun14_11.e069963.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.04.028"},{"key":"2025110101542143000_381.jun14_11.e069963.33","doi-asserted-by":"publisher","DOI":"10.1215\/03616878-10041163"},{"key":"2025110101542143000_381.jun14_11.e069963.34","unstructured":"White House. President Biden announces prescription drug pricing plan in build back better framework. Press release, 2 Nov 2021. https:\/\/www.whitehouse.gov\/briefing-room\/statements-releases\/2021\/11\/02\/president-biden-announces-prescription-drug-pricing-plan-in-build-back-better-framework\/"},{"key":"2025110101542143000_381.jun14_11.e069963.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15268"},{"key":"2025110101542143000_381.jun14_11.e069963.36","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2018.823"},{"key":"2025110101542143000_381.jun14_11.e069963.37","unstructured":"Bastian A Dua D Mirzahossein S . The use of risk-sharing agreements to manage costs, mitigate risk, and improve value for pharmaceutical products. J Clin Pathw 2015;September\/October: 43-51."},{"key":"2025110101542143000_381.jun14_11.e069963.38","doi-asserted-by":"publisher","DOI":"10.1586\/erp.12.12"},{"key":"2025110101542143000_381.jun14_11.e069963.39","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300101060"},{"key":"2025110101542143000_381.jun14_11.e069963.40","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4108"},{"key":"2025110101542143000_381.jun14_11.e069963.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62229-1"},{"key":"2025110101542143000_381.jun14_11.e069963.42","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00231"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2022-069963","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2022-069963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:54:33Z","timestamp":1761987273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2022-069963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":42,"alternative-id":["10.1136\/bmj-2022-069963"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2022-069963","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}